If dogs can sense fear, then kids can sense the thing you absolutely don’t want them to touch.

In related news, I can’t seem to locate my keys.

Me: Go get your pajamas on
Him: Ok, Dad

5 minutes later:

The quality of the company matches the weather #MPNSM Naveen Pemmaraju, MD Stephen Oh Ruben A. Mesa, MD

Our recent manuscript addressing Triple-Negative Myelofibrosis clinical-lymphoma-myeloma-leukemia.com/article/S2152-… great work by Luis E. Aguirre, MD Andrew Kuykendall MD Moffitt Cancer Center

We’re pleased to announced that 241 patients have been randomized in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera and that we expect to meet the trial's 250 patient enrollment target by the end of March 2024. (1/2)

We also expect to announce top-line data for the study's 32-week primary efficacy endpoint by the end of the first quarter of 2025.

See the announcement here: yhoo.it/43C2Ikw (2/2)

In the (very near) future, all communication will occur via out of office messages.

I am very excited that our study identifying SHP2 as a possible therapeutic target for patients w/myeloproliferative neoplasms is now published in AmericanJournalofHematology. Thank you to all who made this possible. Garima Pandey Andrew Kuykendall MD Moffitt Cancer Center #MPNsm

onlinelibrary.wiley.com/doi/10.1002/aj…

Rusfertide is a hepcidin mimetic that inhibits absorption and reuse of iron, resulting in physiological inhibition of iron uptake and control of erythrocytosis in patients with polycythemia vera. Read the full REVIVE trial results and Research Summary: nej.md/3SOWbxY

👉👉👉Delighted to share our paper in NEJM ➡️ Results for Ph2 clinical trial of #PTG300 #Rusfertide a novel #HepcidinMimetic for patients with Polycythemia Vera (PV) | #MPNSM | Marina Kremyanskaya, MD, PhD Andrew Kuykendall MD Naveen Pemmaraju, MD et al MD Anderson Cancer Center #endcancer

nejm.org/doi/full/10.10…

Excited to see this published in NEJM. Phase 2 results of REVIVE - studying the efficacy of the hepcidin mimetic, rusfertide in phlebotomy dependent patients with PV. #MPNSM . Phase 3 VERIFY study is ongoing. Naveen Pemmaraju, MD Aaron Gerds MD, MS Jeanne M Palmer Abdulraheem Yacoub Moffitt Cancer Center

Early Efficacy With Fedratinib in MDS/MPN and CNL Warrants Its Continued Evaluation Moffitt Cancer Center #mpnsm onclive.com/view/early-eff…

So... how is 'fridge' short for refrigerator, if there is no 'd' in refrigerator. Also, frigid doesn't have a 'd.' So the problem lies with 'fridge' which should be frige. But,that's clearly wrong too... ok... back to work🤔

👉👉👉An extremely successful MPN episode of Heme Reports this evening ! Thank you all for joining wow! Pls check out the entire program here!

Tania Jain Hannah Goulart Hima Atluri, MD Jayastu Senapati Ranjit Kumar Sahoo Dineshbhurani Anandi(she/her) @anandikrishnan.bsky🇮🇳🇺🇸

#MPNSM

twitter.com/i/spaces/1yNGa…

#LifeHack , if what you're proposing doesn't make a ton of sense, and you really don't want to have to explain it, just say that it is your internal policy. That should take care of it.

Really enjoyed filming this series of videos on #MPNSM at #ASH23 with Gaby Hobbs, Prithviraj Bose, Pankit Vachhani, and Ashwin Kishtagari, MD. Glad to see them online! onclive.com/peer-exchange/…

I love playing any game with my kids where my role is to pretend that I’m asleep. I’m so good at it.

Every so often, you talk yourself into thinking you're living a healthy lifestyle and then you catch yourself pouring Celsius powder into a lukewarm cup of water and chasing elk jerkey with a loose Christmas cookie that's been in a tin can for 2 weeks. Am I right Gaby Hobbs?

onclive.com/view/dr-sallma…

#mpnresearch #mpnsm #medtwitter

Revisiting 2023 new year’s goals… looks like I have 4 days to write two papers, weigh less, be stronger, and get more organized. Fortunately, 2024 is a leap year, so I’ll have a bit more time to accomplish my goals.